Examples of IDH1 inhibitors include ivosidenib (Tibsovo) and olutasidenib (Rezlidhia), two FDA-approved IDH1 inhibitors used in the treatment of relapsed or refractory AML with susceptible IDH1 mutations [60]. Here, IDH1 is linked to acute myeloid leukemia.